Generic Name and Formulations:
Guselkumab 100mg/mL; soln for SC inj; preservative-free.
Janssen Biotech, Inc.
Indications for TREMFYA:
Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
≥18yrs: 100mg by SC inj at Weeks 0 and 4, then every 8 weeks thereafter.
<18yrs: not established.
Use under physician supervision. May increase risk of infections. Chronic or history of recurrent infection: consider the risks and benefits. If a serious infection develops or is not responding to standard therapy, monitor closely and discontinue until resolves. Evaluate for tuberculosis (TB) infection and treat latent TB prior to initiating. Monitor for signs/symptoms of active TB during and after therapy. Patients with active TB infection: do not initiate. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiation. Consider completion of all age appropriate immunizations according to current guidelines before starting therapy. Pregnancy. Nursing mothers.
Concomitant live vaccines: not recommended. Concomitant CYP450 substrates with narrow therapeutic index: monitor and adjust dose as needed.
Upper respiratory infections, headache, inj site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, herpes simplex infections.
Single-dose prefilled syringe—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline